Model Medicines partners with Sandford Prebys Medical

By The Science Advisory Board staff writers

March 24, 2021 -- Artificial intelligence (AI) drug discovery software developer Model Medicines has signed a deal with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.

The collaboration leverages Model Medicines' ActivPred AI drug discovery platform with Sanford Burnham Prebys' identification of novel antiviral targets and scientific expertise to discover and develop new treatments for SARS-CoV-2 and other infectious diseases. The digital chemistry drug development platform identifies novel biological targets that cannot be resolved with traditional high-throughput screening approaches.

Financial details of the collaboration were not disclosed.

Researchers discover potent inhibitors of SARS-CoV-2 main protease
Researchers have identified protein compounds that are potent inhibitors of the SARS-CoV-2 main protein, a key enzyme that enables the replication of...
How can biopharma innovation be maintained after COVID-19?
Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel...
Improving melanoma immunotherapies by regulating Treg proliferation
A new pathway to regulating anti-tumor immunity and increasing the effectiveness of PD-1 therapies was identified by scientists at Sanford Burnham Prebys...

Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter